Evidence map›Paper›PMID 41959742›Full record

ReviewGenes & diseases2026

Renata Ivo Vasconcelos, Luciana da Torre Carneiro, Raquel Ciuvalschi Maia, Thaís Hancio, Gabriela Nestal de Moraes

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Renata Ivo VasconcelosInstituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro (UFRJ), Avenida Carlos Chagas Filho, 373, 2° andar, H2-003, Cidade Universitária, Rio de Janeiro 21 941 599, Brazil.
Luciana da Torre CarneiroInstituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro (UFRJ), Avenida Carlos Chagas Filho, 373, 2° andar, H2-003, Cidade Universitária, Rio de Janeiro 21 941 599, Brazil.
Raquel Ciuvalschi MaiaPrograma de Hemato-Oncologia Molecular, Instituto Nacional do Câncer (INCA), Praça da Cruz Vermelha, 23, 6° andar, Centro, Rio de Janeiro 20 230 130, Brazil.
Thaís HancioLaboratório Nacional de Biociências (LNBio), Centro Nacional de Pesquisa em Energia e Materiais (CNPEM), Polo II de Alta Tecnologia, R. Giuseppe Máximo Scolfaro, 10000, Bosque das Palmeiras, Campinas, São Paulo 13 083 100, Brazil.
Gabriela Nestal de MoraesInstituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro (UFRJ), Avenida Carlos Chagas Filho, 373, 2° andar, H2-003, Cidade Universitária, Rio de Janeiro 21 941 599, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FOXK2 is a transcription factor known to regulate a wide range of biological processes that are critically involved in determining cell fate. Increasing evidence shows aberrant FOXK2 expression in some tumors, with crucial biological and clinical impacts. It is important to note that the molecular mechanisms contributing to

Indexed as

CancerClinical outcomesFOXK2 transcription factorGene alterationsTranscript expression

Identifiers

PMID41959742
PMCPMC13058959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.